Literature DB >> 9388487

Cell cycle-dependent phosphorylation of p27 cyclin-dependent kinase (Cdk) inhibitor by cyclin E/Cdk2.

H Morisaki1, A Fujimoto, A Ando, Y Nagata, K Ikeda, M Nakanishi.   

Abstract

The cyclin-dependent kinase (Cdk) inhibitor p27 interrupts progression of the cell cycle by inhibiting various cyclin/Cdk activities. Since the protein level of p27 does not correlate with its mRNA level or protein synthesis rate in most cases, it is suggested that degradation of the protein may be regulated via an unidentified mechanism(s) involving a post-translational modification(s). We present evidence here that p27 phosphorylation is cell cycle-dependent and peaks in the late G1 phase and that the level of p27 protein is inversely correlated with its phosphorylation. Although both cyclin D1- and cyclin-E-dependent kinases are active in the late G1 phase in human fibroblasts, cyclin E/Cdk2 specifically phosphorylates p27 on threonine-187 in vitro. Interestingly, ectopic expression of T187A revealed that it was far more stable in vivo than wild type p27. Thus, phosphorylation of p27 by cyclin E/ Cdk2 may affect the stability of its protein and play a role in how the protein functions.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9388487     DOI: 10.1006/bbrc.1997.7590

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  14 in total

1.  Extracellular matrix modulates enterocyte growth via downregulation of c-jun but is independent of p21 and p27 expression.

Authors:  S I Wolpert; K M Lally; J Li; J Y Wang; B L Bass
Journal:  J Gastrointest Surg       Date:  1999 May-Jun       Impact factor: 3.452

2.  The B56gamma3 regulatory subunit of protein phosphatase 2A (PP2A) regulates S phase-specific nuclear accumulation of PP2A and the G1 to S transition.

Authors:  Ting-Yuan Lee; Tai-Yu Lai; Shin-Chih Lin; Cheng-Wei Wu; In-Fan Ni; Yu-San Yang; Liang-Yi Hung; Brian K Law; Chi-Wu Chiang
Journal:  J Biol Chem       Date:  2010-05-06       Impact factor: 5.157

3.  The cyclin-dependent kinase inhibitor SCH 727965 (dinacliclib) induces the apoptosis of osteosarcoma cells.

Authors:  Wei Fu; Le Ma; Baoky Chu; Xue Wang; Marilyn M Bui; Jennifer Gemmer; Soner Altiok; W Jackson Pledger
Journal:  Mol Cancer Ther       Date:  2011-04-13       Impact factor: 6.261

4.  Phosphorylation of nuclear MyoD is required for its rapid degradation.

Authors:  A Song; Q Wang; M G Goebl; M A Harrington
Journal:  Mol Cell Biol       Date:  1998-09       Impact factor: 4.272

5.  Selective effects of PD-1 on Akt and Ras pathways regulate molecular components of the cell cycle and inhibit T cell proliferation.

Authors:  Nikolaos Patsoukis; Julia Brown; Victoria Petkova; Fang Liu; Lequn Li; Vassiliki A Boussiotis
Journal:  Sci Signal       Date:  2012-06-26       Impact factor: 8.192

6.  p21cip1 Degradation in differentiated keratinocytes is abrogated by costabilization with cyclin E induced by human papillomavirus E7.

Authors:  F Noya; W M Chien; T R Broker; L T Chow
Journal:  J Virol       Date:  2001-07       Impact factor: 5.103

7.  Expression of Spy1 protein in human non-Hodgkin's lymphomas is correlated with phosphorylation of p27 Kip1 on Thr187 and cell proliferation.

Authors:  Qinglei Hang; Min Fei; Sicong Hou; Qichao Ni; Cuihua Lu; Guowei Zhang; Peipei Gong; Chengqi Guan; Xianting Huang; Song He
Journal:  Med Oncol       Date:  2012-04-11       Impact factor: 3.064

Review 8.  Molecular pathology of pituitary adenomas.

Authors:  R V Lloyd
Journal:  J Neurooncol       Date:  2001-09       Impact factor: 4.130

Review 9.  p27kip1: a multifunctional cyclin-dependent kinase inhibitor with prognostic significance in human cancers.

Authors:  R V Lloyd; L A Erickson; L Jin; E Kulig; X Qian; J C Cheville; B W Scheithauer
Journal:  Am J Pathol       Date:  1999-02       Impact factor: 4.307

10.  Spy1 interacts with p27Kip1 to allow G1/S progression.

Authors:  Lisa A Porter; Monica Kong-Beltran; Daniel J Donoghue
Journal:  Mol Biol Cell       Date:  2003-07-11       Impact factor: 4.138

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.